Sarepta Therapeutics, Inc. SRPT | NASDAQ
Next Earnings: May 06, 2025
Company Overview:
6.3 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
SRPT Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for SRPT
Based on past 6.3-year performance, here are SRPT growth metrics:
Share price CAGR of -11.92%
Dividend CAGR of +0%
Using SRPT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| SRPT (DRIP) | SRPT - No DRIP | |
|---|---|---|
| Current Price | $62.78 | $62.78 |
| Start Shares | 159.29 | 159.29 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 159.29 | 159.29 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $20.02 | $62.78 |
| Total Dividends | $0 | $0 |
| Final Value | $3,189 | $10,000 |
NOTE: Above numbers are our estimate based on SRPT's Dividend and Price CAGR over past 6.3 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Sarepta Therapeutics, Inc. (SRPT) had its IPO on 1997-06-04, and is trader on NASDAQ stock exchange.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT website: https://www.sarepta.com
